Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Influenza vaccine and risk of acute myocardial infarction in a population-based case-control study.

Autor: José de Abajo, Francisco, Rodríguez-Martín, Sara, Barreira, Diana, Rodríguez-Migue, Antonio, Fernández-Antón, Encarnación, Gil, Miguel, García-Lledó, Alberto, de Abajo, Francisco José, Rodríguez-Miguel, Antonio

Publikováno v: Heart; Jul2022, Vol. 108 Issue 13, p1039-1045, 7p

Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project

Autor: Huerta, Consuelo, Abbing-Karahagopian, Victoria, Requena, Gema, Oliva, Belén, Alvarez, Yolanda, Gardarsdottir, Helga, Miret, Montserrat, Schneider, Cornelia, Gil, Miguel, Souverein, Patrick C, De Bruin, Marie L, Slattery, Jim, De Groot, Mark C H, Hesse, Ulrik, Rottenkolber, Marietta, Schmiedl, Sven, Montero, Dolores, Bate, Andrew, Ruigomez, Ana, García-Rodríguez, Luis Alberto, Johansson, Saga, de Vries, Frank, Schlienger, Raymond G, Reynolds, Robert F, Klungel, Olaf H, de Abajo, Francisco José, Sub Gen. Pharmacoepi and Clinical Pharm, Sub Clinical Pharmacy, Pharmacoepi, Sub Pharmacoepidemiology, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Pharmacoepidemiology and Drug Safety, 25(S1). John Wiley and Sons Ltd

PURPOSE: Studies on drug utilization usually do not allow direct cross-national comparisons because of differences in the respective applied methods. This study aimed to compare time trends in BZDs prescribing by applying a common protocol and analys

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::2baa9b0c5b924c356a6b02935933cb48
https://dspace.library.uu.nl/handle/1874/316727

Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project.

Autor: Huerta C; Division of Pharmacoepidemiology and Pharmacovigilance, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Abbing-Karahagopian V; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands., Requena G; Pharmacology Unit, Department of Biomedical Sciences II, School of Medicine and Health Sciences, University of Alcalá, Madrid, Spain., Oliva B; Division of Pharmacoepidemiology and Pharmacovigilance, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Alvarez Y; European Medicines Agency (EMA), London, UK., Gardarsdottir H; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.; Department of Clinical Pharmacy, Division Laboratory and Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands., Miret M; Merck KGaA, Geneva, Switzerland., Schneider C; Division Clinical Pharmacy and Epidemiology, University of Basel, Switzerland., Gil M; Division of Pharmacoepidemiology and Pharmacovigilance, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Souverein PC; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands., De Bruin ML; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands., Slattery J; European Medicines Agency (EMA), London, UK., De Groot MC; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands., Hesse U; National Institute for Health Data and Disease Control, Copenhagen, Denmark., Rottenkolber M; Institute for Medical Information Sciences, Epidemiology, and Biometry, Ludwig-Maximilians-Universitaet München, Munich, Germany., Schmiedl S; Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.; Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany., Montero D; Division of Pharmacoepidemiology and Pharmacovigilance, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain., Bate A; Epidemiology, Pfizer Ltd, Tadworth, UK., Ruigomez A; Spanish Center for Pharmacoepidemiological Research (CEIFE), Madrid, Spain., García-Rodríguez LA; Spanish Center for Pharmacoepidemiological Research (CEIFE), Madrid, Spain., Johansson S; AstraZeneca R&D, Mölndal, Sweden., de Vries F; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.; MRC Epidemiology Resource Centre, Southampton General Hospital, Southampton, UK.; School CAPHRI, Maastricht University, The Netherlands., Schlienger RG; Quantitative Safety and Epidemiology, Novartis Pharma AG, Basel, Switzerland., Reynolds RF; Epidemiology, Pfizer Research & Development, New York, USA., Klungel OH; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.; University Medical Center Utrecht (UMCU), Julius Center for Health Sciences and Primary Care, The Netherlands., de Abajo FJ; Pharmacology Unit, Department of Biomedical Sciences II, School of Medicine and Health Sciences, University of Alcalá, Madrid, Spain.; Clinical Pharmacology Unit, University Hospital Príncipe de Asturias, Madrid, Spain.

Publikováno v: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2016 Mar; Vol. 25 Suppl 1, pp. 56-65. Date of Electronic Publication: 2015 Jul 07.